A follow-on offering brought in $184 million for MyoKardia. The first patient in a late-stage Explorer-HCM study assessing its drug candidate mavacamten as a treatment of symptomatic, obstructive hypertrophic cardiomyopathy will be dosed this quarter.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.